Agilent Announces New Library Preparation System for Next Generation Sequencing
February 28 2019 - 11:00AM
Business Wire
Fully automated Magnis system delivers reproducible results for
molecular laboratories
Agilent Technologies, Inc. (NYSE:
A) today announced a new next-generation sequencing (NGS) library
preparation system designed to easily run complex DNA sequencing
assays with the press of a button.
The fully automated Magnis NGS Prep System includes reagents and
protocols that make it easy to assay multiple genes and complex
genetic aberrations from genomic DNA, including degraded samples
such as formalin-fixed paraffin embedded (FFPE). The Magnis system
will showcase in Agilent’s sponsorship workshop on Friday, March 1
at 2:55 pm at the Advances in Genome Biology and Technology (AGBT)
Conference taking place February 27 – March 2 in Marco Island,
Florida.
“Since the inception of NGS, library preparation has been one of
the most complex and variable parts of the NGS workflow,” stated
Sam Raha, president of the company’s Diagnostics and Genomics
Group. “We are excited to provide a turnkey, automated workflow
solution that is easy to use and increases sequencing
reproducibility, making it a clear choice for any molecular testing
lab interested in the genetic aspects of cancer and other
diseases.”
Providing a complete solution for NGS library preparation, the
Magnis system is fully automated and delivers reproducible results
with one-day turnaround time. It has been designed to run complex
NGS library assays with minimal technical knowledge and hands-on
time.
Incorporating self-detection and tuning capabilities, the Magnis
system also comes with pre-aliquoted reagents and pre-set
protocols. It is fully compatible with Agilent’s SureSelect XT HS
library prep workflow, allowing molecular barcode-based error
correction, as low as 10ng of DNA input, and optimized performance
for poor-quality specimens. Agilent’s focus on easy-to-use,
automated instruments for the pathology lab can also be seen
throughout its Dako portfolio of products, a full breadth of
solutions that include H&E, IHC, ISH, and companion
diagnostics.
When combined with the Agilent 4150 TapeStation, the Magnis
system provides quality control of the sample throughout the NGS
workflow. It also works seamlessly with Agilent’s industry-leading
SureSelect target enrichment system coupled with Agilent’s Alissa
Clinical Informatics Platform to deliver sequencing results from
desktop sequencers that
are robust, traceable, and reproducible.
Requiring minimal expertise to run, the Magnis system combines
an onboard wizard that enables assays to be set up in under
five minutes, and system notification of correct reagent
placement through automated barcode checking. Upon pressing the
start button, the user can walk away from the instrument, yet
visually check assay progress through the wizard and LED status
indicator.
The Magnis system is now available for pre-order and instruments
will begin shipping globally by June 2019. There will be a CE-IVD
marked version of the instrument available in Europe. For more
information visit www.agilent.com/chem/magnis.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Based on more
than 50 years of insight and innovation, Agilent instruments,
software, services, solutions, and people provide trusted answers
to customers’ most challenging questions. The company generated
revenues of $4.91 billion in fiscal 2018 and employs 14,800 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190228005607/en/
Naomi GoumilloutAgilent
Technologies+1.781.266.2819naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024